NCT05118776View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

January 21, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Recurrent Glioblastoma
Interventions
DRUG

ASC40 tablets

ASC40 tablets administered orally once daily

DRUG

Placebo tablets

Placebo administered orally once daily.

DRUG

Bevacizumab

Bevacizumab once every 2 weeks, intravenous drip.

Trial Locations (1)

100071

Beijing Tiantan Hospital，Capital Medical University, Beijing

Sponsors
All Listed Sponsors
lead

Ascletis Pharmaceuticals Co., Ltd.

INDUSTRY

NCT05118776 - Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM | Biotech Hunter | Biotech Hunter